Trial Profile
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Doxorubicin liposomal; Gemcitabine; Paclitaxel; Topotecan
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOLO3
- Sponsors AstraZeneca
- 25 Jul 2022 Status changed from active, no longer recruiting to completed.
- 22 Jul 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 07 Jun 2022 Results of pooled analysis from 4 trials (SOLO1, PAOLA1, SOLO2 and SOLO3) presented at the 58th Annual Meeting of the American Society of Clinical Oncology